

OFFICE OF THE VICE CHANCELLOR FOR RESEARCH

Research Administrators Monthly Meeting October 2018

Peggy Diskin, Associate Director (Proposals) Office of Research Services





- Announcements
- Clinical Trial Budget Basics
- Questions/Discussion





Announcements

Proposal Team Contacts

Thank you Beth!



Clinical Trial Budget Basics

Identify the Components of a Clinical Trial Budget

Identify the hidden costs



Initial Contact from Sponsor

 The sponsor reaches out to potential sites to determine interest and feasibility for conducting a trial

 A pre-study questionnaire may be requested to summarize potential for patient recruitment, staff availability, and existence of needed equipment



Where Do I Start?

What you need:

- The Protocol
 - schedule of events
- The sponsor draft informed consent
- The sponsor draft budget
- The sponsor draft contract



Schedule of Events

Epidural Neuromodulation for Spinal Cord Injury Protocol <#> Version <1.66> <03/07/2017>

Table 2

()

2

| Procedures | Screening | Enroliment | Month 3 | Month 4 | Month 5 | Month 6 | Month 7 | Month 8 | Month 9 | Month 10 | Month 11 | Month 12 | Month 13 | Month 14 | Month 15 |
|---------------------------------------|-----------|------------|---------|---------|---------|---------|---------|---------|---------|----------|----------|----------|----------|----------|----------|
| Spinal Cord Stimulator Implantation | | X | | | | | | | | | | | | | |
| Demographics | x | | | | | | | | | | | | | | |
| General Health History | X | | | | | | | | | | | | | | |
| Epidemiology/Environmental History | x | | | | | | | | | | | | | | |
| History of Disease/Injury Event | x | | | | | | | | | | | | | | |
| Physical Examinations | X | X | X | | | X | | | х | | | х | | | X |
| Vital Signs and Other Body Measures | | | | | | | | | | | | | | | |
| Vital Signs and Tests | x | X | X | x | X | x | x | х | X | X | X | х | X | X | X |
| Laboratory Tests | x | | | | | | | | | | | | | | |
| Spinal Imaging / Spinal Cord Imaging | x | | | | | | | | | | | | | | |
| Treatment / Intervention Data | | | | | | | | | | | | | | | |
| Assistive/Mobility Devices & Orthosis | X | | | | | | | | | | | | | | |
| Falls Diary | X | X | X | X | X | X | X | X | X | X | X | x | X | X | X |
| NBSS | x | x | x | x | X | x | x | x | x | x | x | x | X | X | X |
| NBDS | X | | | | | x | | | | | | | | | X |
| Rehabilitation Therapies | x | | | | | | | | | | | | | | |
| Surgical and Procedural Interventions | X | | | | | | | | | | | | | | |
| Other Investigational Treatments | X | | | | | | | | | | | | | | |
| Home Training | | | X | X | X | x | x | x | x | x | x | x | X | X | X |
| Neurological Outcomes | | | | | | | | | | | | | | | |
| Classification of SCI | X | | | | | | | | | | | | | | |
| Modified Ashworth Scale | X | | X | | | X | | | X | | | × | | | X |
| NINDS Myotatic Reflex Scale | X | | | | | | | | | | | | | | |
| Electrodiagnostics | | | | | | | | | | | | | | | |
| Brain Motor Control Assessment | X | | X | X | X | X | X | X | X | X | X | X | X | X | X |
| Device electrode mapping | | X | X | | | X | | | X | | | X | | | X |
| Standing Training Assessment | | | X | | | X | | | X | | | × | | | × |
| Functional Outcomes | X | | | | | | | | | | | | | | |
| Autonomics | | | | | | | | | | | | | | | |
| Autonomic Screening | x | | | | | | | | | | | | | | |
| Autonomic Assessments | | | а | | | а | | | а | | | | | | |
| Sympathetic Skin Responses | | | а | | | | | | а | | | | | | |
| Cognitive | | | а | | | а | | | а | | | | | | |
| Pain | X | | X | | | X | | | X | | | х | | | × |
| Psychological | X | | X | | | X | | | X | | | х | | | X |
| Quality of Life | X | | X | | | х | | | X | | | х | | | X |
| Sleep | X | | X | | | X | | | X | | | X | | | × |

Items are grouped according to the major categories of 7.1.1 in blue. Categories containing elements administered at different times in the study are expanded and grayed out. 'X' represents mandatory assessments for all subjects. 'a' represents assessments for subjects selected to undergo autonomics protocol.

Coverage Analysis

| A Fonts * Colors * A Fonts * Effects * Themes | ins Oriental | * | Print Br Area * e Setup | eaks Backgrou | nd Print | Given Width | nt: 1 pag | je – | Gridling Vie Prir Sheet | w 💌 v | View Print | Bring to Send to Selection Align Group Front Back Pane Arrange | Rotate | |
|--|----------------------------|--|-------------------------------|---------------|------------------------------------|------------------|-----------------------------|--------------------------------|----------------------------------|---------------------|-----------------|--|---|--|
| A2 B udy Title: otocon number: incipal Investigator: werage Analysis Vers | | | | | | | | | | | | | | |
| This Coverage A | | | | | | | | | | | | reithird party payers based upon current illable must be supported by medical nec | | |
| Items and Services | Protocol | CPT/HCPC | Q1/Q0 Modifier | Prescreening | Screening | (cy | cle=28 d Cycles n | ays) Every 16 | Po: End-of- | st treatme | ent | Comments | Biller Summary | |
| | Location | S Codes | s | . resorcening | ≤35 Days Prior to Randomization | Cycle 1 Day 1 | Day 1 (±2 days) | weeks (Starting on C1D1) | Treatment | Safety Follow-up | Follow | | | |
| ould Dx Code ¥70.7 (and 0 pear on the claim? | condition Cod | le 30, where ap | plicable) | No | No | Yes | Yes | Yes | Yes | No | Yes | | | |
| ne & Effort Informed Consent | Prot. P. 83 | NKA | No | NA | NA | | | | | | | This is not a billable item or service. | Non-billable; research related. | |
| Inclusion/Exclusion Criteria | Prot. P. 83 | N/A | No | 1925 | NA | | | | | | | This is not a billable item or service. | Non-billable; research related. | |
| Randomization Adverse Events ¹ | Prot. P. 83 Prot. P. 84 | N/A N/A | No No | NA | NA NA | NA | NA | NA | NA | NA | | This is not a billable item or service. This is not a billable item or service. | Non-billable; research related. Non-billable; research related. | |
| Concomitant Medications ² | Prot. P. 84 | N/A | No | 196 | NA | NA | NA | NA | NA | NA | | This is not a billable item or service. | Non-billable; research related. | |
| Medical Resource | Prot. P. 83 | N/A | No | | | NA | NA | | | | | This is not a billable item or service. | Non-billable; research related. | |
| Utilization Progression on First | Prot. P. 84 | N/A | No | | | | | | | | NA* | This is not a billable item or service. | Non-billable; research related. | |
| Subsequent Therapy | | | | | | | | | | | | | | |
| FACT-P and EQ-5D Study Drug Compliance | Prot. P. 84 Prot. P. 83 | N/A N/A | No No | | | NA | NA NA | | NA NA | | NA ³ | This is not a billable item or service. This is not a billable item or service. | Non-billable; research related. Non-billable; research related. | |
| aluation & Management | Services | | | | | | | | | | | | | |
| Physical Examination | Prot. P. 84 | 99201 - 99205; 99211 - 99215 G0463 | Q1 or No | | B | N | N | | N | | | Per Institutional Policy, any item or service performed at baseline/soreening is not billable unless medical necessity is documented. Subjects in this study must have documented non- | Non-billable; requires documentation of medical necessity to bill at screening. Billable during treatment and post-treatment. | |
| | | | | | | | | | | | | metastatic (M0) oastration-resistant prostate cancer (Protocol, 38). The investigational drug is known to cause significant side effects (ICF, p. 18). A physical exam during treatment and at end of treatment is appropriate for the clinical management of the patient and to monitor, assees, and treat for | | |
| | | | | | | | | | | | | potential complications associated with the study | | |
| Medical/Oncological | Prot. P. 83 | N/A | No | | R | | | | | | | drugs. Coverage supported by NCD 310.1. This is not a separately billable item or service. | Not separately billable; included in physical | |
| History ECOG | Prot. P. 83 | N/A | No | | B | N | N | | N | | | This is not a separately billable item or service. | exam. Not separately billable; included in physical | |
| | Prot. P. 84 | N/A | No | | B | | N | | N | | | | exam. | |
| Vital Signs | Prot. P. 84 | INFA | 100 | | - | N | | | N | | | This is not a separately billable item or service. | Not separately billable; included in physical exam. | |
| bs PSA | Prot. PP. 83, | 84153 | No | B' | | | | | | | | Per Institutional Policy, any item or service performed | Non-billable: requires documentation of | |
| | 85 | 01100 | | | | | | | | | | at baseline/screening is not billable unless medical necessity is documented. | medical necessity to bill at screening. | |
| | | | | | | | | | | | | Note: Per NCD 190.31, PSA is a marker used to follow the progress of prostate cancer once a diagnosis has been established. | | |
| Venipuncture | N/A | 36415 or 36592 | No | R | | | | | | | | This item is provided in conjunction with research laboratory testing. To the extent that the laboratory test is covered, so is the venipuncture. | To the extent that the laboratory test is covered, so is the venipuncture. | |
| | | | | | | CL | CL | | | | | All laboratory assessments will be performed by a | Non-billable; sent to central laboratory. | |
| ntral Labs CBC w/diff and Platelets | Prot. PP. 83, | 36415 or 36592 | No | | CL | | | | CL | | | | | |



Sponsor Draft Budget

| Procedures | Total Quan tity | Selected Cost | Visit 1 - Screening | Visit 2 - Day 1 | Visit 3 - Week 1 | Visit 4 - Week 4 | Visit 5 - Week 8 | Visit 6 - Week 12 | Visit 7 - Week 16 | Visit 8 - Week 20 | Visit 9 - Week 24 | Visit 10 - Week 28 | Visit 11 - Week 32 | Visit 12 - Week 36 | Visit 13 - Week 40 | Visit 14 - Week 44 | Visit 15 - Week 48 | Visit 16 - Week 52 (End of Study) | Total |
|---|-----------------------|------------------|------------------------|--------------------|---------------------|---------------------|---------------------|----------------------|----------------------|----------------------|----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|---|-----------|
| Informed Consent | 1.00 | 150.00 | 150.00 | | | | | | | | | | | | | | | | 150.00 |
| Complete Physical (Med Hx, Height, | 1.00 | 215.00 | 215.00 | | | | | | | | | | | | | | | | 215.00 |
| Comp. Follow-Up Visit w Phys/Vitals | 1.00 | 180.00 | | | | | | | | | | | | | | | | 180.00 | 180.00 |
| Vital Signs | 13.00 | 25.00 | | 25.00 | | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | | 325.00 |
| ECG | 3.00 | 125.00 | 125.00 | | | | | 125.00 | | | | | | | | | | 125.00 | 375.00 |
| Review Concomitant Medications | 16.00 | 35.00 | 35.00 | 35.00 | 35.00 | 35.00 | 35.00 | 35.00 | 35.00 | 35.00 | 35.00 | 35.00 | 35.00 | 35.00 | 35.00 | 35.00 | 35.00 | 35.00 | 560.00 |
| Intravitreal Injection of REGN2176-3 Or | 13.00 | 400.00 | | 400.00 | | 400.00 | 400.00 | 400.00 | 400.00 | 400.00 | 400.00 | 400.00 | 400.00 | 400.00 | 400.00 | 400.00 | 400.00 | | 5,200.00 |
| BCVA | 16.00 | 90.00 | 90.00 | 90.00 | 90.00 | 90.00 | 90.00 | 90.00 | 90.00 | 90.00 | 90.00 | 90.00 | 90.00 | 90.00 | 90.00 | 90.00 | 90.00 | 90.00 | 1,440.00 |
| Fluorescein Angiography | 4.00 | 300.00 | 300.00 | | | | | 300.00 | | | | 300.00 | | | | | | 300.00 | 1,200.00 |
| Fundus Photography | 4.00 | 115.00 | 115.00 | | | | | 115.00 | | | | 115.00 | | | | | | 115.00 | 460.00 |
| SD-OCT | 16.00 | 110.00 | 110.00 | 110.00 | 110.00 | 110.00 | 110.00 | 110.00 | 110.00 | 110.00 | 110.00 | 110.00 | 110.00 | 110.00 | 110.00 | 110.00 | 110.00 | 110.00 | 1,760.00 |
| Ocular Blood Flow by Repetitive IOP | 28.00 | 88.00 | 88.00 | 176.00 | | 176.00 | 176.00 | 176.00 | 176.00 | 176.00 | 176.00 | 176.00 | 176.00 | 176.00 | 176.00 | 176.00 | 176.00 | 88.00 | 2,464.00 |
| Indirect Ophthalmoscopy | 28.00 | 90.00 | 90.00 | 180.00 | | 180.00 | 180.00 | 180.00 | 180.00 | 180.00 | 180.00 | 180.00 | 180.00 | 180.00 | 180.00 | 180.00 | 180.00 | 90.00 | 2,520.00 |
| Slit Lamp | 15.00 | 100.00 | 100.00 | 100.00 | | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 1,500.00 |
| Venipuncture/Sample Handling | 12.00 | 20.00 | 20.00 | 20.00 | | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | | | | 20.00 | 240.00 |
| Urinalysis | 5.00 | 30.00 | 30.00 | | | | | 30.00 | | | 30.00 | | | 30.00 | | | | 30.00 | 150.00 |
| Adverse Events Assessment | 16.00 | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 | 800.00 |
| | | Procedure: | 1,518.00 | 1,186.00 | 285.00 | 1,186.00 | 1,186.00 | 1,756.00 | 1,186.00 | 1,186.00 | 1,216.00 | 1,601.00 | 1,186.00 | 1,216.00 | 1,166.00 | 1,166.00 | 1,166.00 | 1,333.00 | 19,539.00 |
| | | 30.00% | 455.40 | 355.80 | 85.50 | 355.80 | 355.80 | 526.80 | 355.80 | 355.80 | 364.80 | 480.30 | 355.80 | 364.80 | 349.80 | 349.80 | 349.80 | 399.90 | 5,861.70 |
| Per Patient Pro | cedur | e Subtotal: | 1,973.40 | 1,541.80 | 370.50 | 1,541.80 | 1,541.80 | 2,282.80 | 1,541.80 | 1,541.80 | 1,580.80 | 2,081.30 | 1,541.80 | 1,580.80 | 1,515.80 | 1,515.80 | 1,515.80 | 1,732.90 | 25,400.70 |
| | | | | | | | | | | | | | | | | | | | |
| Other Direct Costs | Total | Selected | Visit 1 - | Visit 2 - | Visit 3 - | Visit 4 - | Visit 5 - | Visit 6 - | Visit 7 - | Visit 8 - | Visit 9 - | Visit 10 - | Visit 11 - | Visit 12 - | Visit 13 - | Visit 14 - | Visit 15 - | Visit 16 - | Total |
| | Quan | Cost | Screening | Day 1 | Week 1 | Week 4 | | | | | | | | | | | | Week 52 (End | |
| Physician's Fees without Exam Costs | 16.00 | 130.00 | 130.00 | 130.00 | 130.00 | 130.00 | 130.00 | 130.00 | 130.00 | 130.00 | 130.00 | 130.00 | 130.00 | 130.00 | 130.00 | 130.00 | 130.00 | 130.00 | |
| Salaries: Coord, Nurse, Admin, Tech | 16.00 | 165.00 | 165.00 | 165.00 | 165.00 | 165.00 | 165.00 | 165.00 | 165.00 | 165.00 | 165.00 | 165.00 | 165.00 | 165.00 | 165.00 | 165.00 | 165.00 | 165.00 | 2,640.00 |
| Pharmacy Dispensing | 13.00 | 20.00 | | 20.00 | | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | | 260.00 |
| Patient Daily Reimbursement | 16.00 | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 | 800.00 |
| Per Patient (| | | 345.00 | 365.00 | 345.00 | 365.00 | 365.00 | 365.00 | 365.00 | 365.00 | 365.00 | 365.00 | 365.00 | 365.00 | 365.00 | 365.00 | 365.00 | 345.00 | 5,780.00 |
| | | 30.00% | 103.50 | 109.50 | 103.50 | 109.50 | 109.50 | 109.50 | 109.50 | 109.50 | 109.50 | 109.50 | 109.50 | 109.50 | 109.50 | 109.50 | 109.50 | 103.50 | 1,734.00 |
| Per Patient Other D | Direct (| Cost Totals: | 448.50 | 474.50 | 448.50 | 474.50 | 474.50 | 474.50 | 474.50 | 474.50 | 474.50 | 474.50 | 474.50 | 474.50 | 474.50 | 474.50 | 474.50 | 448.50 | 7,514.00 |

Cost Per Patient Totals: 2,421.90 2,016.30

819.00 2,016.30 2,016.30 2,757.30 2,016.30

2,016.3

2,055.3

2,555.8

2,016.3

2,055.3

1,990.3

1,990.3

1,990.3

2,181.40

| Invoice Items | | | | | | | | | | |
|-------------------------------------|---------------|------------------|----------|--|--|--|--|--|--|--|
| Name | Total Quan | Selected Cost | Total | | | | | | | |
| Archiving/Document storage/per site | 1.00 | 650.00 | 650.00 | | | | | | | |
| Closeout Fee | 1.00 | 1,000.00 | 1,000.00 | | | | | | | |
| Initial IRB Fee | 1.00 | 5,000.00 | 5,000.00 | | | | | | | |
| IRB Renewal | Each Year | | | | | | | | | |
| IRB Amendment | 1.00 | 750.00 | 750.00 | | | | | | | |
| Site Start-up Costs | 1.00 | 5,000.00 | 5,000.00 | | | | | | | |
| Initial Pharmacy Fee | 1.00 | 3,900.00 | 3,900.00 | | | | | | | |
| Annual Pharmacy Fee | Each | | | | | | | | | |
| SAE report prep fee | Each | | | | | | | | | |
| Screen Failure | Each | 2,421.90 | | | | | | | | |
| Serum Pregnancy Test, Quantitative | 2.00 | 39.00 | 78.00 | | | | | | | |
| Urine Pregnancy Test, Qualitative | 13.00 | 20.00 | 260.00 | | | | | | | |



32,914.70

Industry Sponsored Budget Components

- Personnel Costs
- Procedures
- Labs
- Pharmacy Fees
- Subject Stipends
- Overhead



Personnel Costs

- Study Personnel need "effort" estimates by time (mins/hrs/per visit) and typical personnel and their estimated salary/benefits (MD Investigator, clinical study coordinator (RN), non RN trial coordinator, …) for each item on the Schedule of Events (SOE)
 - Effort must include salary and fringe benefits
- UIC FY19 Fringe Benefit Rate: 35.15%



Procedures

Labs

Obtain research rates for each clinical procedure

- Laboratory fees
 - Lab panels vs. individual tests
- Central labs vs local labs
- Overnight shipping
- Radiology
- Clinical supplies
- Pharmacokinetics
 - Serial collections
- Tumor Tissue Collection
 - Fresh Tissue vs. Archival Tissue



Pharmacy Fees

Study Drug and Administration

- Infusion vs. IV push vs. Subcutaneous Injection vs. Oral
- Provided by Sponsor vs. Commercially Available
- Dispensing and storage charges

Contact the Investigational Drug Service at UI Health



Subject Stipends

- Meals
- **Transportation**
 - Site Provided or Mileage Reimbursement
 - Parking Stickers

Sponsor may pay study subject directly



Don't Forget to Consider. . .

- Study Start-Up
 - Staff Training
 - Recruitment Activities
- Staff Time
 - Review of Serious Unexpected Serious Events (SUSAR)
 - Investigational New Drug (IND) Reports
 - Remote Monitoring
 - Upload Documents
 - Archive document storage fee \$ rate /year for 7 years
 - Source document binders per subject



Don't Forget to Consider. . .

- IRB Review
- IRB Continuing Review Fee
- IRB Amendment Review
- IRB Preparation Fee



Overhead on Industry Sponsored Clinical Trials

Indirect Cost Rate (IDC) for Industry Sponsored Studies

The UIC indirect cost rate of 25% TDC (Total Direct Cost Base) applies to ALL procedural and non-procedural line items, as well as, to items that must be invoiced



Budgeting for Federally Funded Clinical Trials

- Effort covers all PI's work, including professional fees for clinical services and procedures
- Clinical procedures are to be priced at the research rate for Governmentallyfunded research (obtain from UI Health Research Administration)
 - General administrative expenses should not be included as direct costs on the budget
 - Use current applicable fringe benefit rate (35.15%) and F&A rate (59.9% MTDC)



NEGOTIATE NEGOTIATE NEGOTIATE

- Prepare in advance
- Negotiate
- Be prepared to walk away



Why is all of this important?

As a non-profit institution, UIC must recover the full cost of research conducted for outside sponsors, including all associated operating costs (overhead). To do otherwise would result in subsidizing for-profit research and could jeopardize the institution's non-profit status.

Clinical Trials at UIC

For Externally Sponsored Clinical Trials (Industry sponsored/Federally funded/Private Foundation funded)

- Coverage Analysis
- Clinic/Hospital Request for Services Form
- IRB Application
- ORS contract review
- Clinic/Hospital Research Services Billing study participants need to be placed on the research bill hold



Clinical Trials at UIC

For Principal Investigator (PI) Sponsored Clinical Trials or Department Funded Clinical Trials (no external funding or thirdparty sponsor)

- Coverage Analysis
- Clinic/Hospital Request for Services Form
- IRB Application
- Clinic/Hospital Research Services Billing study participants need to be placed on the research bill hold



UIC QUESTIONS

UIC Clinical Trials Website:

http://research.uic.edu/ct

covanlysis@uic.edu


scottken@uic.edu

- Coverage Analysis:
- Clinic/Hospital request for services:
- Clinic/Hospital budget review: scottken@uic.edu
- Clinic/Hospital research services billing: scottken@uic.edu
- Contract Review:

awards@ic.edu



Questions/Discussion





-Wednesday, November 28th from 1-2pm

Topic: Subawards and Sub-recipient monitoring

